Marshall Wace, LLP Galmed Pharmaceuticals Ltd. Transaction History

Marshall Wace, LLP

  • $77.3 Billion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2019

Feb 14, 2020
SELL
$3.61 - $6.75 $82,448 - $154,163
-22,839 Closed
0 $0
Q3 2019

Nov 14, 2019
BUY
$4.62 - $7.11 $105,516 - $162,385
22,839 New
22,839 $109,000

About Galmed Pharmaceuticals Ltd.

GLMD Quotes by TradingView
  • Ticker GLMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,088,400
  • Market Cap $75.8M
  • Description
  • Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or t...
More about GLMD
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email